| Ji, Li Li |
NCT05607680: A Study of IBI362 in Participants With Obesity or Overweight |
|
|
| Completed | 3 | 610 | RoW | Placebo, IBI362 | Innovent Biologics (Suzhou) Co. Ltd. | Obesity Or Overweight | 08/23 | 04/24 | | |
NCT05093855: Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 2 | 41 | RoW | BDB-001 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 08/23 | 08/23 | | |
NCT05103423: Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 1/2 | 50 | RoW | BDB-001 Injection, Placebo | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 07/23 | 07/23 | | |
| Xia, Jian |
NCT05859516: Application of Point-of-care Ultrasound in Rapid Assessment of Cardiac Arrest Patients |
|
|
| Recruiting | N/A | 50 | RoW | Ultrasound | Zhongnan Hospital | Cardiac Arrest, Point-of-care Ultrasound, Cardiopulmonary Resuscitation | 01/24 | 06/24 | | |
NCT06667063: Clinical Study on the Immune Response Characteristics of Novel Coronavirus and Influenza Virus Infection |
|
|
| Recruiting | N/A | 130 | RoW | Nasal swab/Nasopharyngeal swab/Blood sample collection, Nasal swab/Nasopharyngeal swab/Blood draw | Zhongnan Hospital, Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China | COVID-19, Influenza | 12/24 | 06/25 | | |
NCT05922540: a Cohort Study of Ischemic Cerebrovascular Disease |
|
|
| Recruiting | N/A | 5000 | RoW | Intravenous thrombolysis | Xiangya Hospital of Central South University | Ischaemic Stroke | 11/26 | 11/27 | | |
| Su, Juan |
NCT05793892: Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults |
|
|
| Completed | 3 | 286 | RoW | Lidocaine tetracaine cream, test drug:CU-30101, control drug:Pliaglis | Cutia Therapeutics（Wuxi）Co.,Ltd | Analgesia | 08/23 | 10/23 | | |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 400 | RoW | HB0017 Q4W, HB0017 Q8W, placebo | Huabo Biopharm Co., Ltd. | Psoriasis | 08/24 | 12/25 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
NCT05531682: A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 2 | 160 | RoW | Placebo, HB0017, HB0017 dosing regimens | Huabo Biopharm Co., Ltd. | Plaque Psoriasis | 05/23 | 01/24 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT06802848: Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real) |
|
|
| Not yet recruiting | N/A | 1000 | RoW | Xeligekimab injection | Chongqing Genrix Biopharmaceutical Co., Ltd, Xiangya Hospital of Central South University | Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis, Palmoplantar Psoriasis, Genital Psoriasis | 03/26 | 12/26 | | |
| Recruiting | N/A | 10000 | RoW | NIS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis | 07/30 | 07/30 | | |
